Abstract
Genome-wide screens in mammalian cells have emerged as a powerful tool for determining the relationship of
individual genes to a chosen biological phenotype. However, biological systems often rely on the concerted
action of multiple genes at once to elicit phenotypes. Nowhere is this more evident than in cellular differentiation,
where cell state transitions often involve the modulation of 5-7 master regulatory factors. Consistent with this
observation, successful efforts to reprogram cells, from Yamanaka on, have generally found that simultaneous
expression of 3-5 transcription factors are needed to elicit cell state or type changes (similar to an “AND-gate-
like” genetic circuit), and others have improved the efficiency or accuracy of these transitions by further perturbing
other factors such as epigenetic remodelers. Given these observations, we posit that the ability to carry out highly
combinatorial forward genetic screens for cell state phenotypes would produce a “sea change” in our ability to
engineer cells with highly specific properties, transforming the quality of cells available for research and cell
therapy applications. To this end, we propose an iterative platform that leverages a large multiplicity of
perturbation (MOP) per cell, intelligent structuring of engineered perturbation libraries, and machine learning
approaches to both identify combinations of perturbations most likely to elicit specific cellular phenotypes, and
to engineer maximally informative new perturbation libraries. We have piloted this platform on a simple “toy
model” wherein the simultaneous expression of 6 different proteins (across a total universe of 30 different
potential factors) are required to elicit a phenotype. By overloading cells with ~14 perturbations per cell,
structuring a library of ~80 perturbation combinations, then identifying further observations that would provide
maximal information about the causative perturbation combination, we were able to confidently uncover this six-
input “AND-gate” underlying state logic. While this initial ability to “solve” highly polygenic phenotypes is exciting,
challenges to extending our platform to primary human cells include identification and minimization of dominant
negative perturbations, identification of optimal MOP for each biological question, perfection of methods for high
MOP of primary cells, exploration and optimization of the direction and mechanism of gene expression
perturbation, and the engineering or selection of state changes sufficiently durable for therapeutic utility. We plan
to initially apply this platform to the trans-differentiation of naive T cells into regulatory T cells and the generation
of inexhaustible T-cells for cell therapies, with an eye toward establishing collaborations to deploy this platform
to develop diverse cell types with regenerative or therapeutic value. In short, we posit that complex,
therapeutically relevant phenotypes demand a polygenic design language that reflects the combinatorial
vocabulary and grammar of human biology. We anticipate that our cell engineering platform will provide the first
native implementation of this language.
Public Health Relevance Statement
Narrative
Cellular state changes generally require the simultaneous action of a handful of master regulators, substantially
limiting the robust, durable, stable engineering of cell state for therapeutic application that can be achieved with
current methods for modulating the expression of individual genes. We plan to move beyond the standard one-
perturbation-per-gene paradigm for linking genes to phenotypes by engineering a platform for highly
combinatorial cell state perturbation. We anticipate this platform, which combines both novel wetlab approaches
for engineering highly combinatorial libraries producing a high multiplicity of perturbation with computational
approaches to deconvolve these signals and iteratively engineer maximally informative libraries, will provide a
match between the inherent polygenic complexity of cellular systems and our ability to rationally perturb these
systems to elicit ideal therapeutically-relevant phenotypes.
No Sub Projects information available for 1DP1HG013599-01
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 1DP1HG013599-01
Patents
No Patents information available for 1DP1HG013599-01
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 1DP1HG013599-01
Clinical Studies
No Clinical Studies information available for 1DP1HG013599-01
News and More
Related News Releases
No news release information available for 1DP1HG013599-01
History
No Historical information available for 1DP1HG013599-01
Similar Projects
No Similar Projects information available for 1DP1HG013599-01